ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

ClinicalTrials.gov ID: NCT00280566

Public ClinicalTrials.gov record NCT00280566. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 8:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects With Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer (vs Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of Response to Open-Label Treatment With Both Agents

Study identification

NCT ID
NCT00280566
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
584 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Ziprasidone Oral Capsule Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2005
Primary completion
Apr 30, 2008
Completion
Apr 30, 2008
Last update posted
Mar 24, 2021

2005 – 2008

United States locations

U.S. sites
73
U.S. states
26
U.S. cities
62
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35226
Pfizer Investigational Site Birmingham Alabama 35294
Pfizer Investigational Site Birmingham Alabama 35924
Pfizer Investigational Site Scottsdale Arizona 85251
Pfizer Investigational Site Little Rock Arkansas 72223
Pfizer Investigational Site Costa Mesa California 92626
Pfizer Investigational Site Los Angeles California 90026
Pfizer Investigational Site National City California 91950
Pfizer Investigational Site Sacramento California 95823
Pfizer Investigational Site San Diego California 92108
Pfizer Investigational Site Temecula California 92590
Pfizer Investigational Site Temecula California 92591
Pfizer Investigational Site Altamonte Springs Florida 32701
Pfizer Investigational Site Fort Lauderdale Florida 33319
Pfizer Investigational Site Fort Myers Florida 33912
Pfizer Investigational Site Jacksonville Florida 32216
Pfizer Investigational Site Maitland Florida 32751
Pfizer Investigational Site Miami Florida 33016
Pfizer Investigational Site Miami Florida 33126
Pfizer Investigational Site North Miami Florida 33161
Pfizer Investigational Site Orlando Florida 32806
Pfizer Investigational Site Tavares Florida 32778
Pfizer Investigational Site Decatur Georgia 30033
Pfizer Investigational Site Smyrna Georgia 30080
Pfizer Investigational Site Honolulu Hawaii 96826
Pfizer Investigational Site Des Plaines Illinois 60016
Pfizer Investigational Site Libertyville Illinois 60048
Pfizer Investigational Site Naperville Illinois 60540
Pfizer Investigational Site Naperville Illinois 60563
Pfizer Investigational Site Oak Brook Illinois 60523
Pfizer Investigational Site Schaumburg Illinois 60194
Pfizer Investigational Site Terre Haute Indiana 47802
Pfizer Investigational Site Topeka Kansas 66606
Pfizer Investigational Site Wichita Kansas 67207
Pfizer Investigational Site Lexington Kentucky 40509
Pfizer Investigational Site Owensboro Kentucky 42301
Pfizer Investigational Site Baltimore Maryland 21285
Pfizer Investigational Site Rockville Maryland 20852
Pfizer Investigational Site Pittsfield Massachusetts 01201
Pfizer Investigational Site Taunton Massachusetts 02780
Pfizer Investigational Site Olive Branch Mississippi 38654
Pfizer Investigational Site Ridgeland Mississippi 39157
Pfizer Investigational Site Saint Charles Missouri 63301
Pfizer Investigational Site Lincoln Nebraska 68506
Pfizer Investigational Site Lincoln Nebraska 68510
Pfizer Investigational Site Omaha Nebraska 68131
Pfizer Investigational Site Las Vegas Nevada 89106
Pfizer Investigational Site Nashua New Hampshire 03060
Pfizer Investigational Site Paramus New Jersey 07652
Pfizer Investigational Site Teaneck New Jersey 07666
Pfizer Investigational Site Buffalo New York 14215
Pfizer Investigational Site Olean New York 14760
Pfizer Investigational Site Rochester New York 14618
Pfizer Investigational Site Raleigh North Carolina 27609
Pfizer Investigational Site Cincinnati Ohio 45267-0559
Pfizer Investigational Site Columbus Ohio 43210
Pfizer Investigational Site Toledo Ohio 43609
Pfizer Investigational Site Bethany Oklahoma 73008
Pfizer Investigational Site Oklahoma City Oklahoma 73103
Pfizer Investigational Site Oklahoma City Oklahoma 73116
Pfizer Investigational Site Media Pennsylvania 19063
Pfizer Investigational Site Pittsburgh Pennsylvania 15206
Pfizer Investigational Site Pittsburgh Pennsylvania 15213
Pfizer Investigational Site Memphis Tennessee 38117
Pfizer Investigational Site Arlington Texas 76012
Pfizer Investigational Site Austin Texas 78756
Pfizer Investigational Site Bellaire Texas 77401
Pfizer Investigational Site Dallas Texas 75231
Pfizer Investigational Site Dallas Texas 75390-9121
Pfizer Investigational Site DeSoto Texas 75115
Pfizer Investigational Site Houston Texas 77008
Pfizer Investigational Site Houston Texas 77054
Pfizer Investigational Site Houston Texas 77057

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00280566, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 24, 2021 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00280566 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →